Search results for "Reumatologia"

showing 10 items of 126 documents

Macrophage phenotype in the subclinical gut inflammation of patients with ankylosing spondylitis

2014

OBJECTIVE: Long-term evolution of subclinical gut inflammation to overt Crohn's disease (CD) has been described in AS patients. The aim of this study was to evaluate macrophage polarization occurring in the inflamed gut of patients with AS. METHODS: Twenty-seven HLA-B27(+) AS patients, 20 CD patients and 17 normal controls were consecutively enrolled. Classic M1 (iNOS(+)IL-10(-)), resolution phase (iNOS(+)IL-10(+)), M2 and CD14(+) macrophages were characterized by immunohistochemistry and flow cytometry. Quantitative gene expression analysis of IFN-γ, IL-4, IL-5, IL-33 and STAT6 was performed by real time PCR. RESULTS: Classic M1 macrophages were expanded in CD and AS, where resolution phas…

AdultMalePathologymedicine.medical_specialtymedicine.medical_treatmentCD14BiopsyMacrophage-activating factorMacrophage polarizationInflammationReal-Time Polymerase Chain ReactionM2 macrophageYoung AdultRheumatologyIleumMedicineMacrophageHumansPharmacology (medical)Spondylitis AnkylosingAgedbusiness.industryMacrophagesresolution phase macrophagesDNAIleitisMiddle AgedFlow CytometryImmunohistochemistryInterleukin 10Settore MED/16 - Reumatologiaankylosing spondylitiCytokinePhenotypeGene Expression RegulationM1 macrophages M2 macrophages ankylosing spondylitis gut inflammation interleukin 33 resolution phase macrophagesImmunologyCytokinesFemalegut inflammationinterleukin 33medicine.symptombusinessCD163M1 macrophage
researchProduct

A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy

2014

Introduction Hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE type I) or dysfunction (C1-INH-HAE type II) is a rare disease characterized by recurrent episodes of edema with an estimated frequency of 1:50,000 in the global population without racial or gender differences. In this study we present the results of a nationwide survey of C1-INH-HAE patients referring to 17 Italian centers, the Italian network for C1-INH-HAE, ITACA. Methods Italian patients diagnosed with C1-INH-HAE from 1973 to 2013 were included in the study. Diagnosis of C1-INH-HAE was based on family and/or personal history of recurrent angioedema without urticaria and on antigenic and/or functional C1-INH def…

AdultMalePediatricsmedicine.medical_specialtyAdolescentPopulationNationwide surveyC1-inhibitorYoung AdultmedicineHumansGenetics(clinical)C1 inhibitor; C4; Hereditary angioedema; Adolescent; Adult; Angioedemas Hereditary; Female; Humans; Italy; Male; Middle Aged; Young Adult; Medicine (all); Genetics (clinical); Pharmacology (medical)Pharmacology (medical)Young adulteducationGenetics (clinical)C4Medicine(all)Hereditary angioedemaeducation.field_of_studyC1 inhibitorAngioedemabiologybusiness.industryResearchMedicine (all)Angioedemas HereditaryAngioedemasGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseSettore MED/16 - ReumatologiaHereditaryItalyHereditary angioedemabiology.proteinFemalemedicine.symptomDifferential diagnosisbusinessRare diseaseOrphanet Journal of Rare Diseases
researchProduct

Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis …

2013

OBJECTIVES: Interleukin (IL)-23 has been implicated in the pathogenesis of ankylosing spondylitis (AS). The aim of the study was to clarify the mechanisms underlying the increased IL-23 expression in the gut of AS patients. METHODS: Consecutive gut biopsies from 30 HLA-B27(+) AS patients, 15 Crohn's disease (CD) patients and 10 normal subjects were obtained. Evidence for HLA-B27 misfolding was studied. Unfolded protein response (UPR) and autophagy were assessed by RT-PCR and immunohistochemistry. The contribution of UPR and autophagy in the regulation of IL-23 expression was evaluated in in vitro experiments on isolated lamina propria mononuclear cells (LPMCs). RESULTS: Intracellular coloca…

AdultMaleProtein FoldingBiopsyImmunologyATG5Gene ExpressionInflammationdigestive systemArticleGeneral Biochemistry Genetics and Molecular BiologyATG12Young AdultCrohn DiseaseRheumatologyDownregulation and upregulationSettore BIO/13 - Biologia Applicataankylosing spondylitisAutophagymedicineInterleukin 23HumansImmunology and AllergySpondylitis AnkylosingHLA-B27 AntigenAgedMucous Membranebusiness.industryAutophagyInterleukinIleitisMiddle AgedIntestinesInterleukin 23Settore MED/16 - ReumatologiaImmunologyInterleukin-23 Subunit p19Unfolded Protein ResponseUnfolded protein responseFemalemedicine.symptombusinessAnnals of the Rheumatic Diseases
researchProduct

Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.

2014

OBJECTIVE: The aim of this study was to evaluate the role of rituximab (RTX) in modulating the expression of the IL-17/IL-23 pathway in the salivary glands (SGs) of patients with primary SS (pSS). METHODS: Consecutive SG biopsies were obtained from 15 patients with pSS before and after 1 year of RTX therapy. The SG expression of IL-17, IL-23p19 and p-STAT3 was evaluated by immunohistochemistry at baseline and after RTX therapy. The role of mast cells in pSS patients in modulating the Th17 response and the immunologic effect of RTX on mast cells were also studied in in vitro experiments. RESULTS: IL-17 was overexpressed in the SGs of patients with pSS mainly by infiltrating T cells and mast …

AdultMaleSTAT3 Transcription FactorSjogren SyndromeApoptosisIn Vitro TechniquesInterleukin-23Peripheral blood mononuclear cellSalivary GlandsAntibodies Monoclonal Murine-DerivedRheumatologystomatognathic systemSettore BIO/13 - Biologia ApplicataBiopsyHumansMedicinePharmacology (medical)Mast CellsAgedmedicine.diagnostic_testbusiness.industryInterleukinsInterleukin-17IL17Middle AgedMast cellIn vitroSettore MED/16 - ReumatologiaSjogren's SyndromeTreatment Outcomemedicine.anatomical_structureApoptosisAntirheumatic AgentsImmunologyTh17 CellsImmunohistochemistryFemaleRituximabInterferonsInterleukin 17businessRituximabSignal Transductionmedicine.drug
researchProduct

Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database

2021

ObjectiveThe role of age in influencing the severity of fibromyalgia (FM) is still controversial. The aim of this study is to define the contribution of age in the severity of FM from data from a large national database.MethodsThis cross-sectional study included adult patients with FM diagnosed according to the 2010/2011 American College of Rheumatology criteria. Disease severity was assessed with the revised Fibromyalgia Impact Questionnaire (FIQR) and the modified Fibromyalgia Assessment Status (FAS 2019mod). Patients were grouped into five age categories (between 18-40 years, between 41- 50 years, between 51-60 years, between 61-70 years, and =71 years). Differences in disease severity b…

AdultMaleSettore MED/16 - REUMATOLOGIAAdolescentImmunologyReproducibility of ResultsMiddle AgedFAS 2019mod.Severity of Illness IndexYoung AdultCross-Sectional StudiesRheumatologyagenational databaseSurveys and QuestionnairesQuality of LifeImmunology and AllergyHumansdisease severityFemalefibromyalgiaFIQR
researchProduct

Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic scler…

2017

Objective To evaluate occult cardiac involvement in asymptomatic systemic sclerosis (SSc) patients by pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance (CMR), for a very early identification of patients at higher risk of cardiac-related mortality. Methods Sixteen consecutive patients with definite SSc, fulfilling the American College of Rheumatology/European League Against Rheumatism 2013 classification criteria in less than 1 year from the onset of Raynaud's phenomenon, underwent pharmacological stress, rest perfusion and delayed enhancement CMR. At enrollment, no patient showed signs and/or symptoms suggestive for cardiac involvement. No patient sho…

AdultMalemedicine.medical_specialtyAdenosineHeart diseaseHeart DiseasesVasodilator AgentsContrast MediaMagnetic Resonance Imaging CineAsymptomaticCardiac magnetic resonance imaging with pharmacological stress; Myocardial perfusion defect; Systemic sclerosis; Systemic sclerosis heart involvement; Rheumatology030218 nuclear medicine & medical imaging03 medical and health sciencesMyocardial perfusion imagingCoronary circulation0302 clinical medicineRheumatologyPredictive Value of TestsInternal medicineCoronary CirculationCardiac magnetic resonance imaging with pharmacological stressMultidetector Computed TomographymedicineHumans030203 arthritis & rheumatologyScleroderma Systemicmedicine.diagnostic_testbusiness.industryMicrocirculationMyocardial Perfusion Imagingmedicine.diseaseRheumatologymyocardial perfusion defectSettore MED/16 - Reumatologiamedicine.anatomical_structureEarly DiagnosisVentriclecardiac magnetic resonance imaging with pharmacological streAsymptomatic Diseasessystemic sclerosis heart involvementSystemic sclerosisFemaleRadiologymedicine.symptombusinessPerfusionsystemic sclerosiRheumatism
researchProduct

The in vitro addition of methotrexate and/or methylprednisolone determines peripheral reduction in Th17 and expansion of conventional Treg and of IL-…

2014

The aim of our study was to evaluate methotrexate (MTX) and methylprednisolone (MP) effect on peripheral Th17 and Treg subsets in patients with rheumatoid arthritis (RA). We enrolled 15 patients (10 early RA and 5 long-standing disease) with active RA and 10 age-matched healthy donors as controls. Frequencies of Th17 and Treg were quantified using flow cytometry before and after in vitro addition of MTX, MP or both drugs. Our results showed a reduction in the overall Th17 population followed by an increase in Th17 IL-10+ and Treg, after in vitro treatment of PBMCs with the drugs in patients with early RA. Long-standing disease patients showed a less evident increase in Treg cells and less e…

AdultMalemedicine.medical_specialtyImmunologyPopulationArthritischemical and pharmacologic phenomenaPeripheral blood mononuclear cellMethylprednisoloneT-Lymphocytes RegulatoryArthritis RheumatoidRheumatologyInternal medicinemedicineImmunology and AllergyHumanseducationRheumatoid arthritieducation.field_of_studybusiness.industryhemic and immune systemsMiddle Agedmedicine.diseaseRheumatologyInterleukin-10TregSettore MED/16 - ReumatologiaMethotrexateMethylprednisoloneRheumatoid arthritis Th17 TregRheumatoid arthritisAntirheumatic AgentsImmunologyTh17 CellsMethotrexateFemaleTh17Interleukin 17businessmedicine.drug
researchProduct

Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 case…

2016

Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokine storm, which is involved in the development of multiple organ failure. In this paper, we investigated clinical data, treatments, and outcome of a homogeneous cohort of 41 adult MAS patients, complicating autoimmune rheumatic diseases. MAS-related death occurred in 17 patients (42.5%) during the follow-up, and older age and increased serum ferritin levels, at the time of diagnosis, were significan…

AdultMalemusculoskeletal diseases0301 basic medicinemedicine.medical_specialtyImmunologyAdult onset Still's disease; Hyperferritinemic syndrome; Macrophage activation syndrome; Adult; Ambulatory Care Facilities; Autoimmune Diseases; Female; Humans; Immunosuppressive Agents; Macrophage Activation Syndrome; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Immunology and Allergy; ImmunologyDiseaseAmbulatory Care FacilitiesAutoimmune Diseases03 medical and health sciences0302 clinical medicineAdult onset Still's diseaseInternal medicineHumansImmunology and AllergyMedicineRetrospective Studies030203 arthritis & rheumatologyAutoimmune diseaseAdult patientsbusiness.industryMortality ratefungiRetrospective cohort studyMiddle AgedPrognosisHyperferritinemic syndromemedicine.diseasebody regionsSettore MED/16 - ReumatologiaTreatment Outcome030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeCohortImmunologyFemalelipids (amino acids peptides and proteins)businessCytokine stormImmunosuppressive Agentshormones hormone substitutes and hormone antagonistsAutoimmunity Reviews
researchProduct

Safety of etanercept therapy in rheumatoid patients undergoing surgery: preliminary report

2009

This is a preliminary report on a case-series of rheumatoid patients that underwent various kinds of elective surgery but did not withdraw etanercept therapy in spite of physician advise. Elective surgery consisted of right knee surgical prosthesis, bilateral cataract, bilateral hallux valgus, right hip prosthesis, bladder stone by cystoscopy and left inguinal hernia. All the patients had a regular healing rate. During follow-up (6-12 months) no one of these patients were suffering from infective complications after surgery. According to same recent literature results, our data suggest that it is the time to value rheumatoid patient preferences through a correct information about cost-benef…

AdultMalemusculoskeletal diseasesmedicine.medical_specialtySettore MED/09 - Medicina InternaPilot ProjectsReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidPostoperative ComplicationsPatient satisfactionRheumatologyInternal medicinemedicineHumansPostoperative PeriodElective surgeryWound Healingmedicine.diagnostic_testTumor Necrosis Factor-alphabusiness.industryContraindicationsGeneral MedicineCystoscopyMiddle Agedmedicine.diseaseRheumatologySurgerySettore MED/16 - ReumatologiaTolerabilityElective Surgical ProceduresImmunoglobulin GRheumatoid arthritisFemaleBiological therapy Decompensated diabetes mellitus Etanercept Polymyalgia rheumatica Steroid therapy.businessAdverse drug reactionmedicine.drugClinical Rheumatology
researchProduct

Development and implementation of the AIDA International Registry for patients with Behçet's disease

2022

AbstractPurpose of the present paper is to point out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients with Behçet’s disease (BD). The Registry is a clinical physician-driven non-population- and electronic-based instrument implemented for the retrospective and prospective collection of real-life data about demographics, clinical, therapeutic, laboratory, instrumental and socioeconomic information from BD patients; the Registry is based on the Research Electronic Data Capture (REDCap) tool, which is thought to collect standardised information for clinical real-life research, and has been rea…

AdultRegistrieAutoinflammatory diseaseRegistrySettore MED/16 - REUMATOLOGIAprecision medicinebehçet’s diseaseSettore MED/38 - Pediatria Generale E SpecialisticaRetrospective StudieInternal MedicineHumansProspective StudiesRegistriesChildinternational registryRetrospective StudiesBehçet's diseaseautoinflammatory diseases; behçet’s disease; international registry; precision medicine; rare diseases; uveitisBehcet Syndromerare diseasesautoinflammatory diseasesProspective StudieUveitiEmergency MedicineuveitisRare diseaseHuman
researchProduct